These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623 [TBL] [Abstract][Full Text] [Related]
7. Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis. Bi X; Zhu X; Duong M; Boudyguina EY; Wilson MD; Gebre AK; Parks JS Arterioscler Thromb Vasc Biol; 2013 Oct; 33(10):2288-96. PubMed ID: 23814116 [TBL] [Abstract][Full Text] [Related]
8. Hepatic Overexpression of Endothelial Lipase Lowers High-Density Lipoprotein but Maintains Reverse Cholesterol Transport in Mice: Role of Scavenger Receptor Class B Type I/ATP-Binding Cassette Transporter A1-Dependent Pathways. Takiguchi S; Ayaori M; Yakushiji E; Nishida T; Nakaya K; Sasaki M; Iizuka M; Uto-Kondo H; Terao Y; Yogo M; Komatsu T; Ogura M; Ikewaki K Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1454-1467. PubMed ID: 29748333 [TBL] [Abstract][Full Text] [Related]
9. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066 [TBL] [Abstract][Full Text] [Related]
10. Aerobic exercise improves reverse cholesterol transport in cholesteryl ester transfer protein transgenic mice. Rocco DD; Okuda LS; Pinto RS; Ferreira FD; Kubo SK; Nakandakare ER; Quintão EC; Catanozi S; Passarelli M Lipids; 2011 Jul; 46(7):617-25. PubMed ID: 21479674 [TBL] [Abstract][Full Text] [Related]
11. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors. Breevoort SR; Angdisen J; Schulman IG Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527 [TBL] [Abstract][Full Text] [Related]
12. Aerobic exercise training enhances the in vivo cholesterol trafficking from macrophages to the liver independently of changes in the expression of genes involved in lipid flux in macrophages and aorta. Pinto PR; Rocco DD; Okuda LS; Machado-Lima A; Castilho G; da Silva KS; Gomes DJ; Pinto Rde S; Iborra RT; Ferreira Gda S; Nakandakare ER; Machado UF; Correa-Giannella ML; Catanozi S; Passarelli M Lipids Health Dis; 2015 Sep; 14():109. PubMed ID: 26377330 [TBL] [Abstract][Full Text] [Related]
13. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Tohyama J; Billheimer JT; Fuki IV; Rothblat GH; Rader DJ; Millar JS Atherosclerosis; 2009 Jun; 204(2):418-23. PubMed ID: 18990393 [TBL] [Abstract][Full Text] [Related]
14. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Tanigawa H; Billheimer JT; Tohyama J; Zhang Y; Rothblat G; Rader DJ Circulation; 2007 Sep; 116(11):1267-73. PubMed ID: 17709636 [TBL] [Abstract][Full Text] [Related]
15. Decreased APOE-containing HDL subfractions and cholesterol efflux capacity of serum in mice lacking Pcsk9. Choi S; Aljakna A; Srivastava U; Peterson BR; Deng B; Prat A; Korstanje R Lipids Health Dis; 2013 Jul; 12():112. PubMed ID: 23883163 [TBL] [Abstract][Full Text] [Related]
16. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Tanigawa H; Billheimer JT; Tohyama J; Fuki IV; Ng DS; Rothblat GH; Rader DJ Circulation; 2009 Jul; 120(2):160-9. PubMed ID: 19564558 [TBL] [Abstract][Full Text] [Related]
17. CETP activity variation in mice does not affect two major HDL antiatherogenic properties: macrophage-specific reverse cholesterol transport and LDL antioxidant protection. Rotllan N; Calpe-Berdiel L; Guillaumet-Adkins A; Süren-Castillo S; Blanco-Vaca F; Escolà-Gil JC Atherosclerosis; 2008 Feb; 196(2):505-13. PubMed ID: 17588582 [TBL] [Abstract][Full Text] [Related]
18. ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. Annema W; Dikkers A; Freark de Boer J; Gautier T; Rensen PCN; Rader DJ; Tietge UJF J Lipid Res; 2012 May; 53(5):929-940. PubMed ID: 22383685 [TBL] [Abstract][Full Text] [Related]
19. Diet-induced dyslipidemia impairs reverse cholesterol transport in hamsters. Tréguier M; Briand F; Boubacar A; André A; Magot T; Nguyen P; Krempf M; Sulpice T; Ouguerram K Eur J Clin Invest; 2011 Sep; 41(9):921-8. PubMed ID: 21299553 [TBL] [Abstract][Full Text] [Related]
20. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]